Abstract:COVID-19 is an infectious disease caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), and according to the World Health Organization (WHO), to date, SARS-CoV-2 has already infected more than 91.8 million people worldwide with 1,986,871 deaths. This virus affects mainly the respiratory system, but the gastrointestinal tract (GIT) is also a target, meanwhile SARS-CoV-2 was already detected in oesophagus, stomach, duodenum, rectum, and in fecal samples from COVID-19 patients. Prolonged GIT manifestations in COVID-19, mainly the diarrhea, were correlated with decreased richness and diversity of the gut microbiota, immune deregulation and delayed SARS-CoV-2 clearance. So, the bidirectional interactions between the respiratory mucosa and the gut microbiota, known as gut-lung axis, are supposed to be involved in the healthy or pathologic immune responses to SARS-CoV-2. In accordance, the intestinal dysbiosis is associated with increased mortality in other respiratory infections, due to an exacerbated inflammation and decreased regulatory or anti-inflammatory mechanisms in the lungs and in the gut, pointing to this important relationship between both mucosal compartments. Therefore, since the mucous membranes from the respiratory and gastrointestinal tracts are affected, in addition to dysbiosis and inflammation, it is plausible to assume that adjunctive therapies based on the modulation of the gut microbiota and re-establishment of eubiosis conditions could be an important therapeutic approach for constraining the harmful consequences of COVID-19. Then, in this review, we summarized studies showing the persistence of SARS-CoV-2 in the gastrointestinal system and the related digestive COVID-19 manifestations, in addition to the literature demonstrating nasopharyngeal, pulmonary and intestinal dysbiosis in COVID-19 patients. Lastly, we showed the potential beneficial role of probiotic administration in other respiratory infections, and discuss the possible role of probiotics as an adjunctive therapy in SARS-CoV-2 infection.

The lung-gut axis and COVID-19

Microbiota Modulation of the Gut-Lung Axis in COVID-19

Gut Microbiome and COVID 19 Role of Probiotics on Gut Lung Axis

Gut-Lung Axis-A Compass to Navigate Microbiome Landscape in COVID-19

Coronavirus infection and gut microbiota

Gastrointestinal Microenvironment and the Gut-Lung Axis in the Immune Responses of Severe COVID-19

Gut-lung axis and dysbiosis in COVID-19

COVID-19 and the Human Gut Microbiome: An Under-Recognized Association

COVID-19 and Gastrointestinal Tract: From Pathophysiology to Clinical Manifestations

Intermodulation of gut-lung axis microbiome and the implications of biotics to combat COVID-19

The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications

Gut and airway microbiota dysbiosis and their role in COVID-19 and long-COVID

Coronavirus Disease (COVID-19) Caused by (SARS-CoV-2) Infections: A Real Challenge for Human Gut Microbiota

COVID-19 and the digestive system: A comprehensive review

Impact of COVID-19 on the Gut: A Review of the Manifestations, Pathology, Management, and Challenges

Gut Microbiome Disruption Following SARS-CoV-2: A Review

Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications

Effective Regulation of Gut Microbiota With Probiotics and Prebiotics May Prevent or Alleviate COVID-19 Through the Gut-Lung Axis

Modulated Gut Microbiota for Potential COVID-19 Prevention and Treatment

Gut Microbiota and COVID-19: Potential Implications for Disease Severity

The Role of Gut Microbiome Supplementation in COVID-19 Management